Effectiveness of Dexmedetomidine as premedication to modify the heart rate response to modified electroconvulsive therapy: a randomized controlled trial

Manjunath Shivapujimath, Nikhita Kalyanshetti, Raghavendra Kalal
{"title":"Effectiveness of Dexmedetomidine as premedication to modify the heart rate response to modified electroconvulsive therapy: a randomized controlled trial","authors":"Manjunath Shivapujimath, Nikhita Kalyanshetti, Raghavendra Kalal","doi":"10.4103/mgmj.mgmj_165_23","DOIUrl":null,"url":null,"abstract":"Background: The present study aims to examine whether using Dexmedetomidine as a premedication can reduce heart rate (HR) and peak HR during modified electroconvulsive therapy (ECT). It is known that the acute hemodynamic stress induced by ECT may elevate the risk of cardiovascular complications in psychiatric patients. Previous research has suggested that β-blockers and α-2 adrenergic agonists effectively alleviate the hyperdynamic responses to ECT. Therefore, the current study seeks to determine whether Dexmedetomidine can offer similar benefits in regulating HR fluctuations during the modified ECT procedure. Materials and Methods: In this prospective, double-blinded, randomized controlled study, a total of 60 psychiatric patients aged between 18 and 50 years, categorized as per the American Society of Anaesthesiologists score I and II, and scheduled for ECT, were included. These patients were randomly divided into two groups: Group D, which received 50 mL of normal saline (NS) with 1 µg/kg of Dexmedetomidine, and Group C, which received 50 mL of NS only. HR measurements were taken every 15 s for 5 min following the modified ECT, and any changes in peak HR were carefully recorded and analyzed. Results: The mean age (years) and weight (kg) in groups C and D were 29.5 ± 7.82 and 32.5 ± 8.37, 59.4 ± 5.33 and 58.6 ± 4.57, respectively. Both groups did not differ significantly concerning age (P = 0.157) and weight (P = 0.519). Statistically, no significant difference in mean HR (baseline, before ECT, and peak HR following ECT within 5 min) was observed between study groups. In group D, the rise in HR was significantly less when compared to group C (P = 0.001). The groups had a significant (P = 0.001) difference in HR before ECT. Conclusions: The administration of Dexmedetomidine at a dose of 1 µg/kg as premedication resulted in a notable decrease in HR and peak HR responses during the modified ECT.","PeriodicalId":52587,"journal":{"name":"MGM Journal of Medical Sciences","volume":"52 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MGM Journal of Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/mgmj.mgmj_165_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The present study aims to examine whether using Dexmedetomidine as a premedication can reduce heart rate (HR) and peak HR during modified electroconvulsive therapy (ECT). It is known that the acute hemodynamic stress induced by ECT may elevate the risk of cardiovascular complications in psychiatric patients. Previous research has suggested that β-blockers and α-2 adrenergic agonists effectively alleviate the hyperdynamic responses to ECT. Therefore, the current study seeks to determine whether Dexmedetomidine can offer similar benefits in regulating HR fluctuations during the modified ECT procedure. Materials and Methods: In this prospective, double-blinded, randomized controlled study, a total of 60 psychiatric patients aged between 18 and 50 years, categorized as per the American Society of Anaesthesiologists score I and II, and scheduled for ECT, were included. These patients were randomly divided into two groups: Group D, which received 50 mL of normal saline (NS) with 1 µg/kg of Dexmedetomidine, and Group C, which received 50 mL of NS only. HR measurements were taken every 15 s for 5 min following the modified ECT, and any changes in peak HR were carefully recorded and analyzed. Results: The mean age (years) and weight (kg) in groups C and D were 29.5 ± 7.82 and 32.5 ± 8.37, 59.4 ± 5.33 and 58.6 ± 4.57, respectively. Both groups did not differ significantly concerning age (P = 0.157) and weight (P = 0.519). Statistically, no significant difference in mean HR (baseline, before ECT, and peak HR following ECT within 5 min) was observed between study groups. In group D, the rise in HR was significantly less when compared to group C (P = 0.001). The groups had a significant (P = 0.001) difference in HR before ECT. Conclusions: The administration of Dexmedetomidine at a dose of 1 µg/kg as premedication resulted in a notable decrease in HR and peak HR responses during the modified ECT.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
右美托咪定作为药物前改善改良电休克治疗的心率反应的有效性:一项随机对照试验
背景:本研究旨在研究右美托咪定作为前用药是否可以降低改良电休克治疗(ECT)期间的心率(HR)和峰值HR。已知电痉挛引起的急性血流动力学应激可增加精神病患者心血管并发症的发生风险。先前的研究表明β-受体阻滞剂和α-2肾上腺素能激动剂能有效缓解ECT的高动力反应。因此,目前的研究旨在确定右美托咪定是否能在调节改良电痉挛治疗过程中的心率波动方面提供类似的益处。材料与方法:在这项前瞻性、双盲、随机对照研究中,共纳入60例年龄在18至50岁之间的精神病患者,根据美国麻醉医师协会评分I和II,并计划进行ECT治疗。将患者随机分为两组:D组给予生理盐水(NS) 50 mL加右美托咪定1µg/kg; C组只给予生理盐水50 mL。在改良电痉挛治疗后的5分钟内,每15秒测量一次心率,仔细记录并分析峰值心率的任何变化。结果:C组和D组的平均年龄(岁)和体重(kg)分别为29.5±7.82、32.5±8.37、59.4±5.33、58.6±4.57。两组在年龄(P = 0.157)和体重(P = 0.519)方面无显著差异。统计学上,各组间平均心率(基线、ECT前、ECT后5分钟内峰值心率)无显著差异。与C组相比,D组HR的上升幅度明显较小(P = 0.001)。两组电痉挛前心率差异有统计学意义(P = 0.001)。结论:给药前给予右美托咪定1µg/kg剂量可显著降低改良电痉挛时的HR和峰值HR反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
23
审稿时长
14 weeks
期刊最新文献
Prevalence of ocular manifestations and related morbidity in severely malnourished children in a tertiary eye care center An evolutionary explanation for increased cesarean section rates Renal-limited systemic lupus erythematosus: Avoiding delay in diagnosis Associative role of methylenetetrahydrofolate reductase and thymidylate synthase 6bp del gene polymorphism in preterm delivery Clinical presentation and fungal species distribution in otomycosis in a tertiary care hospital
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1